FrancophonIA/ELRC3.0 huggingface dataset:
English: България АбВи ЕООД Тел:+359 2 90 30 430
Danish: АбВи ЕООД Тел: +359 2 90 30 430
English: • Wait to remove the needle cover until just before the injection
Danish: • Vent med at fjerne kanylehætten til umiddelbart inden injektionen.
English: Based on population pharmacokinetic analyses, serum creatinine levels, creatinine clearance, or hepatic function markers (ALT/AST/bilirubin) did not have a meaningful impact on risankizumab clearance in subjects with psoriasis.
Danish: Baseret på farmakokinetiske populationsanalyser havde serumkreatininniveauer, kreatinin-clearance eller leverfunktionsmarkører (ALAT/ASAT/bilirubin) ingen relevant indvirkning på risankizumab-clearance hos patienter med psoriasis.
English: Risankizumab may increase the risk of infection.
Danish: Risankizumab kan øge risikoen for infektion.
English: Subjects who were originally on risankizumab and had a sPGA response of clear or almost clear at week 28 were rerandomised to continue risankizumab every 12 weeks or have treatment withdrawn.
Danish: Patienter, der var på risankizumab fra starten og havde en sPGA-score svarende til "clear" eller "almost clear" hud i uge 28, blev genrandomiseret til enten at fortsætte på risankizumab hver 12. uge eller få behandlingen seponeret.
English: Co-primary endpoints versus placebo No impact on health-related quality of life c Psoriasis Symptom Scale (PSS) of 0 means no symptoms of pain, itching, redness, and burning during the last 24 hours
Danish: Ingen indvirkning på den helbredsrelaterede livskvalitet Psoriasis Symptom Scale (PSS) på 0 betyder ingen symptomer på smerter, kløe, rødme og forbrænding i løbet af de sidste 24 timer
English: For the second syringe, inject at least 3 cm away from the first injection.
Danish: Ved injektion nr. 2 skal du injicere med den anden sprøjte mindst 3 cm væk fra det første injektionssted.
English: Pull the needle out of the skin while keeping the syringe at the same angle.
Danish: Træk kanylen ud af huden i den samme vinkel.
English: Solution for injection (injection).
Danish: Injektionsvæske, opløsning (inj.
English: Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Danish: Skyrizi er indiceret til behandling af moderat til svær plaque-psoriasis hos voksne patienter, der er kandidater til systemisk behandling.
English: There is no relevant use of Skyrizi in children aged below 6 years for the indication of moderate to severe plaque psoriasis.
Danish: Det er ikke relevant at anvende Skyrizi hos børn under 6 år i indikationen moderat til svær plaquepsoriasis.
English: Improvements were observed in psoriasis involving the scalp, the nails, and the palms and soles at week 16 and week 52 in subjects treated with risankizumab.
Danish: Der sås bedring af psoriasis i hovedbund, negle samt håndflader og fodsåler i uge 16 og uge 52 hos patienter, der fik risankizumab.
English: Drug interactions between risankizumab and inhibitors, inducers, or substrates of drug metabolising enzymes are not expected and no dose adjustment is needed (see section 5.2).
Danish: Der forventes ingen lægemiddelinteraktioner mellem risankizumab og hæmmere eller inducere af eller substrater for lægemiddelmetaboliserende enzymer, og dosisjustering er ikke nødvendigt (se pkt.
English: Driving and using machines Skyrizi is not likely to affect your driving and use of machines.
Danish: Trafik- og arbejdssikkerhed Det er ikke sandsynligt, at Skyrizi vil påvirke din evne til at føre motorkøretøj og betjene maskiner.
English: Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology.
Danish: Risankizumab er et humaniseret monoklonalt immunglobulin G1 (IgG1)-antistof mod proteinet interleukin (IL)-23, der fremstilles i ovarieceller fra kinesiske hamstere vha. rekombinant dnateknologi.
English: Subjects received treatment at week 0, week 4 and every 12 weeks thereafter.
Danish: Patienterne fik behandling uge 0, uge 4 og derefter hver 12. uge.
English: Do not rub the skin where you have injected.
Danish: Du må ikke gnide på huden ved injektionsstedet.
English: Starting at week 16, subjects who were receiving adalimumab continued or switched treatment based on response:
Danish: Patienter, der fik adalimumab, fortsatte med denne behandling fra og med uge 16 eller skiftede til en anden behandling baseret på respons:
English: Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine without binding to IL12 and inhibits its interaction with the IL-23 receptor complex.
Danish: Risankizumab er et monoklonalt humaniseret immunglobulin G1 (IgG1)-antistof, der binder selektivt og med høj affinitet til p19-underenheden af humant interleukin 23 (IL-23)-cytokin, uden at binde til IL-12 og hæmmer dets interaktion med IL-23-receptor-komplekset.
English: By blocking IL-23 from binding to its receptor, risankizumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.
Danish: Ved at blokere IL-23 og forhindre binding til IL-23 receptorerne hæmmer risankizumab IL-23-afhængig cellesignalering og frigivelse af proinflammatoriske cytokiner.
English: Tel: +354 535 7000
Danish: Sími: +354 535 7000
English: The dose is 150 mg given as two 75 mg injections.
Danish: Dosen er på 150 mg, indgivet som to injektioner a 75 mg.
English: The recommended dose is 150 mg (two 75 mg injections) administered by subcutaneous injection at week 0, week 4, and every 12 weeks thereafter.
Danish: Den anbefalede dosis er 150 mg (to 75 mg-injektioner) administreret subkutant i uge 0, uge 4 og derefter hver 12. uge.
English: • The needle guard will not activate unless all the liquid is injected
Danish: • Kanylebeskyttelsen vil kun blive aktiveret, hvis al opløsningen er injiceret.
English: Before injecting, patients may remove the carton from the refrigerator and allow to reach room temperature out of direct sunlight (15 to 30 minutes) without removing the pre-filled syringes from the carton.
Danish: Inden injektionen kan patienten tage æsken ud af køleskabet og lade de fyldte sprøjter nå stuetemperatur liggende i æsken uden for direkte sollys (i 15-30 minutter).
English: In a study of subjects with psoriasis, expression of genes associated with the IL-23/IL-17 axis was decreased in the skin after single doses of risankizumab.
Danish: I et studie af patienter med psoriasis sås en reduceret ekspression af gener, der er forbundet med IL23/IL-17-aksen, i huden efter enkeltdoser af risankizumab.
English: No overall differences in risankizumab exposure were observed between older and younger subjects who received risankizumab.
Danish: Der sås ingen overordnede forskelle i risankizumab-eksponering mellem de ældre og de yngre patienter, der fik risankizumab.
English: Hold the syringe with the covered needle pointing down, as shown.
Danish: Hold sprøjten med kanylen (med kanylehætte) pegende nedad som vist på figuren.
English: This medicinal product contains less than 1 mmol sodium (23 mg) per 150 mg dose, that is to say essentially ‘sodium free'.
Danish: Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. dosis på 150 mg og er således stort set natriumfrit.
English: • Special disposal container (not included in the carton)
Danish: • Beholder til skarpe genstande (medfølger ikke i æsken)
English: For each dose, the injections should be administered at different anatomic locations (such as thighs or abdomen), and not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis.
Danish: Injektionerne skal administreres forskellige steder, hver gang der indgives en dosis (f.eks. i låret og maveregionen); der må ikke injiceres i områder, hvor huden er øm, erytematøs, hærdet, har blå mærker eller er påvirket af psoriasis.
English: • 2 cotton balls or gauze pads (not included in the carton)
Danish: • 2 stykker vat eller gaze (medfølger ikke i æsken)
English: Week 16 109 (35.9) Week 52 171 (56.3) DLQI 0 or 1
Danish: Uge 16 109 (35,9) Uge 52 171 (56,3) DLQI 0 eller 1
English: The mean terminal elimination half-life of risankizumab ranged from 28 to 29 days in Phase 3 studies in subjects with psoriasis.
Danish: Den gennemsnitlige terminale eliminationshalveringstid for risankizumab var 28-29 dage i fase 3-studier af patienter med psoriasis.
English: Skyrizi is used to treat adults with moderate to severe plaque psoriasis.
Danish: Skyrizi anvendes til behandling af voksne med moderat til svær plaque-psoriasis.
English: IMMHANCE enrolled 507 subjects (407 randomised to risankizumab 150 mg and 100 to placebo).
Danish: IMMHANCE inkluderede 507 patienter (407 var randomiseret til risankizumab 150 mg, og 100 var randomiseret til placebo).
English: Week 12 264 (86.8) Week 52 279 (91.8) PASI 90
Danish: Uge 12 264 (86,8) Uge 52 279 (91,8) PASI 90
English: Table 2: Efficacy and quality of life results in adults with plaque psoriasis in ULTIMMA-1 and ULTIMMA-2
Danish: Tabel 2: Effekt- og livskvalitetresultater hos voksne med plaque-psoriasis i ULTIMMA-1 og ULTIMMA-2
English: Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment.
Danish: Kvinder, der kan blive gravide, skal bruge sikker prævention under behandlingen og i mindst 21 uger efter behandlingens afslutning.
English: • PASI 90 continued to receive adalimumab
Danish: • Patienter med PASI 90 fortsatte med at få adalimumab.
English: A caregiver may also give your injections after they have been trained.
Danish: En omsorgsperson, der er blevet oplært i det, kan også give dig injektionerne.
English: As an IgG1 monoclonal antibody, risankizumab is not expected to be filtered by glomerular filtration in the kidneys or to be excreted as an intact molecule in the urine.
Danish: Som et monoklonalt IgG1-antistof forventes risankizumab ikke at undergå glomerulær filtration i nyrerne eller at blive udskilt som et intakt molekyle i urinen.
English: At week 16, risankizumab was superior to placebo on the co-primary endpoints of sPGA of clear or almost clear (83.5% risankizumab vs 7.0% placebo) and PASI 90 (73.2% risankizumab vs 2.0% placebo).
Danish: I uge 16 var risankizumab superiør i forhold til placebo, hvad angår de co-primære endepunkter, dvs. sPGA svarende til "clear" eller "almost clear" hud (83,5 % for risankizumab vs. 7,0 % for placebo) og PASI 90 (73,2 % for risankizumab vs. 2,0 % for placebo).
English: If you get any side effects, talk to your doctor, pharmacist, or nurse.
Danish: Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken.
English: A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.
Danish: Det skal besluttes, om amning skal ophøre eller behandling med risankizumab undlades, under hensyn til fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
English: Skyrizi is not recommended for children and adolescents under 18 years of age.
Danish: Skyrizi anbefales ikke til børn og unge under 18 år, da lægemidlet ikke er undersøgt hos denne aldersgruppe.
English: Subjects randomised to adalimumab received 80 mg at week 0, 40 mg at week 1 and 40 mg every other week through week 15.
Danish: De patienter, der var randomiseret til adalimumab, fik 80 mg i uge 0, 40 mg i uge 1 og 40 mg hver anden uge frem til og med uge 15.
English: The liquid may contain tiny white or clear particles.
Danish: Opløsningen kan indeholde små hvide eller klare partikler.
English: The mean (±standard deviation) steady-state volume of distribution (Vss) of risankizumab was 11.4 (±2.7) L in Phase 3 studies in subjects with psoriasis, indicating that the distribution of risankizumab is primarily confined to the vascular and interstitial spaces.
Danish: Det gennemsnitlige (± standardafvigelse) steady state-fordelingsvolumen (Vss) for risankizumab var 11,4 (± 2,7) liter i fase 3-studier af patienter med psoriasis, hvilket indikerer, at risankizumabs fordeling primært sker vaskulært og interstitielt.
English: Press a cotton ball or gauze pad where you have injected and hold for 10 seconds.
Danish: Tryk et stykke vat eller gaze mod injektionsstedet i 10 sekunder.
English: Skyrizi is available in packs containing 2 pre-filled syringes and 2 alcohol pads.
Danish: Skyrizi fås i pakninger med 2 fyldte sprøjter og 2 spritservietter.
English: Overall, subjects had a median baseline PASI score of 17.8, a median BSA of 20.0%, and a median baseline DLQI score of 13.0.
Danish: Samlet set havde patienterne en median PASI-score ved baseline på 17,8, en median BSA-værdi på 20,0 % og en median baseline DLQI-score på 13,0. sPGA-scoren ved baseline var høj hos 19,3 % af patienterne og moderat hos 80,7 %.
English: Continued on Adalimumab (N=56) n (%)
Danish: Fortsatte på adalimumab (N = 56) n (%)
English: The mean (±standard deviation) systemic clearance (CL) of risankizumab was 0.3 (±0.1) L/day in Phase 3 studies in subjects with psoriasis.
Danish: Den gennemsnitlige (± standardafvigelse) systemiske clearance (CL) af risankizumab var 0,3 (± 0,1) l/dag i fase 3-studier af patienter med psoriasis.
English: Week 16 200 (65.8) Week 52 229 (75.3) PSS 0 (symptom-free)
Danish: Uge 16 200 (65,8) Uge 52 229 (75,3) PSS 0 (symptomfri)
English: If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.
Danish: Hvis du ammer eller planlægger at amme, skal du tale med lægen, før du tager dette lægemiddel.
English: • if the syringe paper tray cover is broken or missing
Danish: • hvis sprøjtens emballage er brudt eller mangler
English: Skyrizi should not be used if the solution is cloudy or discoloured, or contains large particles.
Danish: Skyrizi bør ikke anvendes, hvis opløsningen er uklar eller misfarvet eller indeholder store partikler.
English: sPGA of clear or almost clear PASI 75
Danish: sPGA svarende til "clear" eller "almost clear" hud
English: Keep the pre-filled syringes in the original carton in order to protect from light.
Danish: Opbevar de fyldte sprøjter i den originale æske for at beskytte mod lys.
English: Risankizumab exhibited linear pharmacokinetics with dose-proportional increase in exposure across dose ranges of 18 to 300 mg and 0.25 to 1 mg/kg administered subcutaneously, and 200 to 1,200 mg and 0.01 to 5 mg/kg administered intravenously.
Danish: Risankizumab udviste lineær farmakokinetik med en dosisproportional stigning i eksponering inden for dosisintervallerne 18-300 mg og 0,25-1 mg/kg ved subkutan administration og 200-1.200 mg og 0,01-5 mg/kg ved intravenøs administration.
English: • PASI 50 to <PASI 90 were re-randomised to either continue adalimumab or switch to risankizumab
Danish: • Patienter med PASI 50 < PASI 90 blev genrandomiseret til enten at fortsætte på adalimumab eller skifte til risankizumab
English: Change at Week 52 (SE)
Danish: Ændring i uge 52 (SE)
English: For subjects who had PASI 50 to <PASI 90 with adalimumab at week 16 and were re-randomised, differences in PASI 90 response rates between switching to risankizumab and continuing adalimumab were noted 4 weeks after re-randomisation (49.1% vs 26.8%, respectively).
Danish: For patienter på adalimumab, der havde PASI 50 til < PASI 90 i uge 16, og som blev genrandomiseret, blev der 4 uger efter genrandomisering konstateret forskelle i PASI 90-responsraterne ved hhv. skift til risankizumab og fortsættelse af adalimumab (hhv. 49,1 % og 26,8 %).
English: Throw away used syringes in a special disposal container.
Danish: Kassér de brugte sprøjter i en beholder til skarpe genstande.
English: Week 52 262 (86.2) sPGA of clear (0) Week 16 112 (36.8) Week 52 175 (57.6) PASI 75
Danish: Uge 52 262 (86,2) sPGA 0 ("clear" hud) Uge 16 112 (36,8) Uge 52 175 (57,6) PASI 75
English: Removing the needle cover:
Danish: Fjern kanylehætten:
English: Risankizumab has no or negligible influence on the ability to drive and use machines.
Danish: Risankizumab påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
English: Change at Week 16 (SE)
Danish: Ændring i uge 16 (SE)
English: In an integrated analysis of subjects receiving risankizumab in ULTIMMA-1 and ULTIMMA-2 for PASI 100 responders at week 16, 79.8% (206/258) of the subjects who continued on risankizumab maintained the response at week 52.
Danish: I en samlet analyse af de patienter, der fik risankizumab i ULTIMMA-1 og ULTIMMA-2, opretholdte 79,8 % (206 ud af 258) af de patienter, der var PASI 100-respondere i uge 16, og som fortsatte med at få risankizumab, responset i uge 52.
English: Tell your doctor, pharmacist or nurse:
Danish: Fortæl det til lægen, apotekspersonaleteller sygeplejersken hvis:
English: Keep the pre-filled syringes in the outer carton in order to protect from light.
Danish: Opbevar de fyldte sprøjter i den ydre æske for at beskytte mod lys.
English: Insert the needle all the way into the skin at about a 45-degree angle using a quick, short movement.
Danish: Med en hurtig, kort bevægelse skal du føre hele kanylen ind i huden i en vinkel på ca. 45 grader.
English: Other medicines and Skyrizi
Danish: Brug af anden medicin sammen med Skyrizi
English: Do not inject yourself with this medicine unless you have been trained by your doctor, pharmacist or nurse.
Danish: Du må ikke selv injicere lægemidlet, hvis lægen, apotekspersonalet eller sygeplejersken ikke har lært dig, hvordan du skal gøre.
English: The pharmacokinetics of risankizumab in paediatric subjects has not been established.
Danish: Farmakokinetikken for risankizumab hos pædiatriske patienter er ikke klarlagt.
English: How much Skyrizi to use
Danish: Så meget Skyrizi skal du bruge
English: You may have slight bleeding from where you injected.
Danish: Det kan godt bløde en lille smule ved injektionsstedet.
English: What you need to know before you use Skyrizi 3.
Danish: Det skal du vide, før du begynder at bruge Skyrizi 3.
English: Risankizumab exhibited linear pharmacokinetics with approximately dose-proportional increases in systemic exposure (Cmax and AUC) in the evaluated dose ranges of 18 to 300 mg or 0.25 to 1 mg/kg subcutaneous administration in healthy subjects or subjects with psoriasis.
Danish: Risankizumab udviste lineær farmakokinetik med omtrent dosisproportionale stigninger i systemisk eksponering (Cmax og AUC) i de undersøgte dosisintervaller på 18-300 mg eller 0,25-1 mg/kg ved subkutan administration hos raske forsøgspersoner eller patienter med psoriasis.
English: If you forget to use Skyrizi, inject a dose as soon as you remember.
Danish: Hvis du har glemt at tage Skyrizi, skal du injicere en dosis, så snart du kommer i tanker om det. Er du i tvivl, så spørg lægen.
English: For PASI 90 responders at week 16, 88.4% (398/450) of subjects maintained the response at week 52.
Danish: 88,4 % (398 ud af 450) af de patienter, der var PASI 90respondere i uge 16, fastholdt responset i uge 52.
English: As an IgG1 monoclonal antibody, risankizumab is mainly eliminated via intracellular catabolism and is not expected to undergo metabolism via hepatic cytochrome P450 enzymes or renal elimination.
Danish: Som et monoklonalt IgG1-antistof elimineres risankizumab primært via intracellulær katabolisering og forventes ikke at blive metaboliseret via cytokrom P450-leverenzymer eller udskilt gennem nyrerne.
English: One pre-filled syringe contains 75 mg risankizumab.
Danish: Én fyldt sprøjte indeholder 75 mg risankizumab.
English: If you forget to use Skyrizi
Danish: Hvis du har glemt at tage Skyrizi
English: • Do not inject into skin that is sore, bruised, red, hard, scarred, or has stretch marks
Danish: • Du må ikke injicere i et område, hvor huden er øm, rød, hærdet, arret eller har blå mærker eller strækmærker.
English: STEP 8
Danish: TRIN 8
English: If you stop using Skyrizi
Danish: Hvis du holder op med at tage Skyrizi
English: solution for injection 2 pre-filled syringes 2 alcohol pads
Danish: Injektionsvæske, opløsning 2 fyldte sprøjter 2 spritservietter
English: ULTIMMA-1 and ULTIMMA-2
Danish: ULTIMMA-1 og ULTIMMA-2
English: Of these subjects, 63.1% (70/111) of subjects re-randomised to continued treatment with risankizumab achieved a sPGA clear response at week 104 compared to 2.2% (5/225) who were re-randomised to withdrawal from risankizumab.
Danish: Blandt disse patienter opnåede 63,1 % (70/111) af dem, der blev genrandomiseret til fortsat behandling med risankizumab, en sPGA-respons svarende til clear i uge 104 sammenholdt med 2,2 % (5/225) af dem, som blev genrandomiseret til ophør af risankizumab-behandling.
English: Other side effects Tell your doctor, pharmacist or nurse if you get any of the following side effects
Danish: Sig det til lægen, apotekspersonalet eller sygeplejersken, hvis du får en eller flere af nedenstående bivirkninger:
English: Do not use Skyrizi
Danish: Brug ikke Skyrizi:
English: Gender or race
Danish: Køn og etnisk oprindelse
English: Patients may self-inject Skyrizi after training in subcutaneous injection technique.
Danish: Patienterne kan selv injicere Skyrizi under huden, når de har lært teknikken.
English: • With the other hand, gently pull the needle cover straight off
Danish: • Med den anden hånd skal du forsigtigt trække kanylehætten af i en lige bevægelse.
English: Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.
Danish: Inden påbegyndelse af behandling med risankizumab hos patienter med latent eller aktiv TB i anamnesen, hvor et adækvat behandlingsforløb ikke kan bekræftes, bør det overvejes at give anti-TBbehandling.
English: Gently pinch the area of cleaned skin with your other hand and hold it firmly.
Danish: Tag forsigtigt fat om den rengjorte hud med fingrene på den anden hånd, og klem hudområdet sammen.
English: • severe itching of the skin, with a red rash or raised bumps
Danish: • kraftig hudkløe med rødt udslæt eller knopper
English: The solution should be colourless to slightly yellow and clear to slightly opalescent.
Danish: Opløsningen skal være farveløs til let gul og klar til let opaliserende.
English: Subjects randomised to risankizumab received 150 mg of treatment at week 0, week 4 and every 12 weeks thereafter.
Danish: De patienter, der var randomiseret til risankizumab, fik 150 mg uge 0, uge 4 og derefter hver 12. uge.
English: Upper respiratory infections
Danish: Infektion i de øvre luftveje
English: Folliculitis
Danish: Follikulitis
English: Boehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Str. 65
Danish: Boehringer Ingelheim Pharma GmbH & Co.
English: • feeling tired or short of breath, cough which will not go away
Danish: • Træthed eller åndenød, vedblivende hoste
English: No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab.
Danish: Der er ikke gennemført specifikke studier til bestemmelse af, hvorvidt nedsat nyre- eller leverfunktion har betydning for risankizumabs farmakokinetik.
English: What Skyrizi looks like and contents of the pack Skyrizi is a clear and colourless to slightly yellow liquid in a pre-filled syringe with needle guard.
Danish: Skyrizi er en klar og farveløs til let gul opløsning i en fyldt sprøjte med kanylebeskyttelse.
English: Anxiety and depression, as measured by the Hospital Anxiety and Depression Scale (HADS), improved in the risankizumab group at week 16 compared with the placebo group.
Danish: HADS-skalaen (Hospital Anxiety and Depression Scale) hos de risankizumab-behandlede patienter end hos de patienter, der fik placebo.
English: The solution is colourless to slightly yellow and clear to slightly opalescent.
Danish: Opløsningen er farveløs til let gul og klar til let opaliserende.
English: 150 mg (two 75 mg injections) 4 weeks after 1
Danish: 150 mg (to injektioner a 75 mg)
English: • The liquid should look clear to slightly yellow and may contain tiny white or clear particles
Danish: • Opløsningen skal være klar til let gul og kan eventuelt indeholde små hvide eller klare partikler.